Search

Your search keyword '"Philippe Montcuquet"' showing total 2 results
Start Over Author "Philippe Montcuquet" Journal cancer chemotherapy and pharmacology
2 results on '"Philippe Montcuquet"'

1. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma

Author

Richard Lauvin, Philippe Montcuquet, Moïse Namer, Claude Jacquillat, Jean-Pierre Bizzari, Bruno Audhuy, J. Bonneterre, Pierre Kerbrat, M. Weil, Pierre Fumoleau, Didier Cupissol, Roland Bugat, Edouard Grosshans, Jean-Jacques Bonerandi, Catherine Vilmer, Chantal Prache, Pierre Banzet, Marie-Françoise Avril, and David Khayat

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Nitrosourea, medicine.medical_treatment, Antineoplastic Agents, Toxicology, Gastroenterology, Drug Administration Schedule, Nitrosourea Compounds, Metastasis, chemistry.chemical_compound, Organophosphorus Compounds, Internal medicine, Humans, Multicenter Studies as Topic, Medicine, Pharmacology (medical), Melanoma, Aged, Pharmacology, Chemotherapy, Brain Neoplasms, business.industry, Remission Induction, Middle Aged, medicine.disease, Surgery, Clinical trial, Regimen, Oncology, chemistry, Toxicity, Drug Evaluation, Fotemustine, Female, Tomography, X-Ray Computed, business, medicine.drug
Abstract

A total of 42 patients with cerebral metastases of malignant melanoma were included in this study of the nitrosourea fotemustine. The treatment plan consisted of a l-h i.v. infusion of 100 mg/m2 fotemustine every week for 3-4 weeks, followed by a 4- to 5-week rest period. Responding or stabilised patients then received 100 mg/m2 fotemustine every 3 weeks. Among the 39 evaluable patients, 2 complete responses and 9 partial responses were documented, leading to an overall response rate of 28.2%. Most of the responses were obtained in previously untreated patients and/or those presenting with a single cerebral metastasis. Toxicity was mild and mainly hematological, especially in patients previously treated by polychemotherapeutic regimen. Our study confirms the activity of fotemustine in cerebral metastases of disseminated malignant melanoma.

Published
1990
Full Text
View/download PDF

2. Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group

Author

Jean-Pierre Bizzari, Edouard Grosshans, Lucien Israel, Michelle Delaunay, Moïse Namer, Philippe Montcuquet, Véronique Arcaute, Marie-Françoise Avril, Pierre Kerbrat, Roland Bugat, Pierre Fumoleau, J. Bonneterre, and Didier Cupissol

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Dacarbazine, Toxicology, Gastroenterology, Nitrosourea Compounds, Metastasis, Organophosphorus Compounds, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Pharmacology (medical), Melanoma, Aged, Pharmacology, Chemotherapy, Leukopenia, business.industry, Combination chemotherapy, Middle Aged, medicine.disease, Oncology, Toxicity, Fotemustine, Female, medicine.symptom, business, medicine.drug
Abstract

A total of 70 patients presenting with a disseminated malignant melanoma were entered into a multicentric study of combination chemotherapy using dacarbazine and fotemustine. In all, 63 patients were evaluable, 31.8% of whom had previously received cytotoxic chemotherapy. The protocol consisted of induction treatment with a weekly infusion of 100 mg/m2 fotemustine on days 1 and 8 and a daily infusion of 250 mg/m2 dacarbazine on days 15/18 followed by a 4- to 5-week rest period. Responding and stabilized patients were given maintenance treatment comprising fotemustine (100 mg/m2, day 1) and dacarbazine (250 mg/m2, days 2/5) every 3 weeks. The response rate was 33.3% (9 complete responses (CRs) and 12 partial responses (PRs)) and was outstanding among pretreated patients (34.9%). Responses were also documented in cerebral (28.6%), visceral (23.1%) and nonvisceral (43.3%) metastatic sites. Toxicity was mainly hematologic (22.2%, grade III/IV leukopenia; 20.3%, grade III/IV thrombocytopenia) and was acceptable. These results are encouraging in terms of the antitumor activity against nonvisceral metastases (43.3%) and the percentage of CRs obtained (23.3%), and they confirm the activity of fotemustine in cerebral metastatic sites.

Published
1990

Catalog

Books, media, physical & digital resources
See catalog results